Dermatology
Atopic Eczema — Assessment and Step-Up Therapy
IGA-based severity assessment and NICE step-up treatment ladder for atopic eczema in adults and children
Source: NICE NG95 2023
Step 1 of ~12
info
Atopic Eczema
Affects 15–20% children, 1–3% adults. Key features: dry skin, pruritus, characteristic distribution (flexures in older children/adults; face/scalp in infants). Assess severity: clear, mild, moderate, severe using IGA (Investigator's Global Assessment) and POEM (Patient-Oriented Eczema Measure).
Related
Curated clinical cross-links plus same-class fallbacks.
Drugs
- Tralokinumab · IL-13 Inhibitor — Atopic Eczema
- Abrocitinib · JAK1 Inhibitor — Atopic Eczema
- Lebrikizumab · IL-13 Inhibitor — Atopic Eczema
- Morphine (Oral) · Strong Opioid Analgesic — Step 3 WHO Ladder
- Oxycodone · Strong Opioid Analgesic — Step 3 WHO Ladder
- Dimethyl Fumarate · Disease-Modifying Therapy — Relapsing-Remitting Multiple Sclerosis
Pathways
- Suspicious Pigmented Lesion — Melanoma Pathway · NICE NG14 2015 / BAD
- Cellulitis and Erysipelas · NICE NG141 2019 / CREST
- Psoriasis — Severity Assessment and Step-Up Therapy · NICE NG153 2019 / BAD
- Urticaria and Angioedema · BSACI / EAACI Guidelines 2022
- Acne Vulgaris — Grading and Treatment · NICE NG198 2021 / BAD
- Non-Melanoma Skin Cancer — BCC and SCC · NICE NG12 2015 / BAD NMSC Guidelines
Decision support only. Always apply local guidelines and clinical judgement.